Biological/Vaccine: Allogeneic HB-adMSCs ( DrugBank: HB-adMSCs )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 1 |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04995081 (ClinicalTrials.gov) | July 16, 2021 | 16/7/2021 | Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) | A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease | Parkinson Disease | Biological: Biological/Vaccine: Allogeneic HB-adMSCs;Other: Placebo | Hope Biosciences Stem Cell Research Foundation | Hope Biosciences | Recruiting | 45 Years | 80 Years | All | 60 | Phase 2 | United States |